现代肿瘤医学
現代腫瘤醫學
현대종류의학
Journal of Modern Oncology
2015年
22期
3262-3265
,共4页
食管癌%紫杉醇%顺铂%奈达铂
食管癌%紫杉醇%順鉑%奈達鉑
식관암%자삼순%순박%내체박
esophageal cancer%paclitaxel%cisplatin%nedaplatin
目的：观察紫杉醇分别联合顺铂、奈达铂治疗晚期食管癌的疗效和毒副反应。方法：收集58例Ⅳ期食管癌患者，分为紫杉醇联合顺铂组（TP）31例和紫杉醇联合奈达铂组（TN）27例，其中紫杉醇注射液135mg／m2，静脉滴注3小时，d1；顺铂25mg／m2，静脉滴注，d1～d3，奈达铂80mg／m2，d1；21天为1个周期。结果：紫杉醇＋顺铂组与紫杉醇＋奈达铂组有效率分别为37．10％和51．85％（P ＝0．315）；两组疾病控制率分别为77．42％和81．48％（P ＝0．703）；两组患者中位无进展生存期分别为6．8和7．8个月（P ＝0．678）；中位总生存期分别为10．4和11．4个月（P ＝0．412），差异均无统计学意义。两组中恶心呕吐、食欲下降两种毒副反应发生率比较，差异有统计学意义（P 值分别为0．009和0．007）。结论：紫杉醇联合顺铂或奈达铂治疗晚期食管癌有效率与生存期无统计学差异，但联合奈达铂方案胃肠道毒副反应较轻。
目的：觀察紫杉醇分彆聯閤順鉑、奈達鉑治療晚期食管癌的療效和毒副反應。方法：收集58例Ⅳ期食管癌患者，分為紫杉醇聯閤順鉑組（TP）31例和紫杉醇聯閤奈達鉑組（TN）27例，其中紫杉醇註射液135mg／m2，靜脈滴註3小時，d1；順鉑25mg／m2，靜脈滴註，d1～d3，奈達鉑80mg／m2，d1；21天為1箇週期。結果：紫杉醇＋順鉑組與紫杉醇＋奈達鉑組有效率分彆為37．10％和51．85％（P ＝0．315）；兩組疾病控製率分彆為77．42％和81．48％（P ＝0．703）；兩組患者中位無進展生存期分彆為6．8和7．8箇月（P ＝0．678）；中位總生存期分彆為10．4和11．4箇月（P ＝0．412），差異均無統計學意義。兩組中噁心嘔吐、食欲下降兩種毒副反應髮生率比較，差異有統計學意義（P 值分彆為0．009和0．007）。結論：紫杉醇聯閤順鉑或奈達鉑治療晚期食管癌有效率與生存期無統計學差異，但聯閤奈達鉑方案胃腸道毒副反應較輕。
목적：관찰자삼순분별연합순박、내체박치료만기식관암적료효화독부반응。방법：수집58례Ⅳ기식관암환자，분위자삼순연합순박조（TP）31례화자삼순연합내체박조（TN）27례，기중자삼순주사액135mg／m2，정맥적주3소시，d1；순박25mg／m2，정맥적주，d1～d3，내체박80mg／m2，d1；21천위1개주기。결과：자삼순＋순박조여자삼순＋내체박조유효솔분별위37．10％화51．85％（P ＝0．315）；량조질병공제솔분별위77．42％화81．48％（P ＝0．703）；량조환자중위무진전생존기분별위6．8화7．8개월（P ＝0．678）；중위총생존기분별위10．4화11．4개월（P ＝0．412），차이균무통계학의의。량조중악심구토、식욕하강량충독부반응발생솔비교，차이유통계학의의（P 치분별위0．009화0．007）。결론：자삼순연합순박혹내체박치료만기식관암유효솔여생존기무통계학차이，단연합내체박방안위장도독부반응교경。
Objective:To evaluate the efficacy and toxicity of the combination of paclitaxel and cisplatin or nedapl-atin for patients with metastatic esophageal cancer.Methods:All 58 patients with metastatic esophageal cancer were divided into two groups.The patients received 135mg/m2 paclitaxel over a 3h infusion on day 1,followed by 25mg/m2 cisplatin On day 1 ~3,or 80mg/m2 nedaplatin on day 1.The treatments were done every 3 weeks.Results:The re-sponse rates were 37.10% and 51.85%(P =0.315),and the disease control rates were 77.42% and 81.48%(P =0.703)in TP and TN groups respectively.The median progression free survival were 6.8 months and 7.8 months(P=0.678),and the median overall survival were 10.4 months and 11.4 months(P =0.412)respectively.The differ-ences all showed no significance.The rates of nausea and vomiting and loss of appetite were different in two groups(P=0.009,P =0.007).The differences were statistically significant.Conclusion:Paclitaxel combined with cisplatin or nedaplatin in the treatment of advanced esophageal cancer have the similar response rate and survival,however,neda-platin regimen shows superiority in gastrointestinal side effects.
